Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations
SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy and safety of sunvozertinib versus platinum-based doublet chemotherapies as a first-line treatment for non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins).
EGFR exon20ins have been difficult to treat due to their unique spatial conformation, diverse mutation subtypes, and high heterogeneity. Patients with EGFR exon20ins NSCLC face a poor prognosis and limited treatment options due to the limited efficacy of first- to third-generation EGFR tyrosine kinase inhibitors (TKIs).
Sunvozertinib, the only oral treatment for NSCLC patients with EGFR exon20ins approved, has demonstrated significant efficacy and a favorable safety profile in this patient population. Both the U.S. Food and Drug Administration (FDA) and the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) have granted Breakthrough Therapy designation to sunvozertinib for the treatment of EGFR exon20ins NSCLC.
WU-KONG28 is a phase III, multinational, randomized clinical trial investigating sunvozertinib compared to platinum-based doublet chemotherapies in treatment-naïve NSCLC patients with EGFR exon20ins. The study is being conducted across 16 countries and regions in Asia, Europe, North America, and South America.
At the 2023 European Society for Medical Oncology (ESMO) Annual Meeting, Dizal reported that sunvozertinib, as a single oral agent, achieved 100% reduction of target lesions, a confirmed objective response rate (ORR) of 78.6%, and a median progression-free survival (mPFS) of 12.4 months, in treatment-naïve patients with advanced or metastatic NSCLC with EGFR exon20ins. In addition, sunvozertinib also demonstrated a well-tolerated safety profile compaired to other EGFR TKIs.
Sunvozertinib is approved in China for the treatment of relapsed and refractory NSCLC with EGFR exon20ins. U.S. FDA granted priority review for its NDA for the same indication with a PDUFA date of July 7, 2025.
About sunvozertinib (DZD9008)
Sunvozertinib is an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity. In August 2023, sunvozertinib received approval from NMPA to treat advanced NSCLC with EGFR exon20ins after platinum-based chemotherapies. The approval is based on the results of WU-KONG6 study, the pivotal study of sunvozertinib in platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins. In addition, sunvozertinib also demonstrated encouraging anti-tumor activity in NSCLC patients with EGFR sensitizing, T790M, and uncommon mutations (such as G719X, L861Q, etc.), as well as HER2 exon20ins.
Sunvozertinib showed a well-tolerated and manageable safety profile in the clinic. The most common drug-related TEAEs (treatment-emergent adverse event) were Grade 1/2 in nature and clinically manageable.
Two global pivotal studies are ongoing in ≥ 2nd line (WU-KONG1 Part B) and 1st line setting (WU-KONG28), respectively, in NSCLC patients with EGFR exon20ins.
Pre-clinical and clinical results of sunvozertinib were published in peer-reviewed journals Cancer Discovery and The Lancet Respiratory Medicine.
About Dizal
Dizal is a biopharmaceutical company, dedicated to the discovery, development, and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio with two approved drugs and multiple assets in global pivotal studies. To learn more about Dizal, please visit www.dizalpharma.com, or follow us on Linkedin or Twitter.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", and "intend" and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal's competitive environment, and political, economic, legal, and social conditions.
Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.
ContactsInvestor Relations: ir@dizalpharma.comBusiness Development: bd@dizalpharma.comMedia Contact: pr@dizalpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/dizal-completes-enrollment-for-its-phase-iii-pivotal-study-of-sunvozertinib-vs-platinum-doublet-in-treatment-naive-nsclc-patients-with-egfr-exon20-insertional-mutations-302486187.html
SOURCE Dizal Pharmaceutical
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
25 minutes ago
- Associated Press
NIA Invites You to Countdown to "SITE 2025" Southeast Asia's Largest Innovation and Startup Expo, uniting 10 Countries and Over 100 Organizations to Drive Global Innovation Collaboration
BANGKOK, THAILAND - Media OutReach Newswire - 20 June 2025 - The National Innovation Agency (Public Organization) or NIA, under the Ministry of Higher Education, Science, Research and Innovation, has announced its readiness to host the Startup x Innovation Thailand Expo 2025 (SITE 2025) under the theme: 'Global Innovation Partnership – AI & Sustainability: The Next Era of Innovation,' to be held from July 4–6, 2025, at Paragon Hall, 5th Floor, Siam Paragon. This year marks a significant milestone as SITE evolves into a truly regional platform for innovation. Thailand is positioning itself as a Global Innovation Collaboration Hub, uniting the strength of 10 leading partner countries: Japan, South Korea, Hong Kong, Singapore, Czech Republic, Hungary, Finland, Switzerland, Qatar, and Chile—spanning Asia, Europe, the Middle East, and Latin America. In addition, over 100 organizations will participate, including 20 international agencies, 12+ leading private-sector companies, 7 professional associations, and 50 universities from across Thailand. IMG 0419 'More Than an Expo – A Global Collaboration Platform' Dr. Krithpaka Boonfueng, Executive Director of NIA, stated: 'SITE 2025 is more than an expo—it's a platform where meaningful global collaboration takes place with depth, inclusivity, and a shared purpose. With AI and sustainability at the core of the global economy, our goal is to drive real-world impact across business, investment, and innovation policy.' The 2025 edition of SITE will feature more than 30 seminars, covering the full spectrum of global innovation across three major stages: Main Stage – the 'heart' of the event, where international thought leaders will share visionary insights and the latest trends in AI, sustainability, and cross-border collaboration. Global Stage – in-depth policy and strategy sessions exploring opportunities, challenges, and pathways to bring innovation to the global market. Pitch Stage – a dedicated arena for Thai and international startups to pitch their ideas, promote technologies, and scale their ventures in front of global investors. Highlights: From Global Policy to Groundbreaking Pitches One of the major highlights on the Pitch Stage will be the National Pitching Startup Thailand League 2025, alongside the 100 Startup Pitching showcase, featuring cutting-edge technologies such as AI, Deep Tech, and sustainability-driven innovation. The expo will also include exhibitions from over 300 startups and leading innovation organizations, presenting real products, prototypes, and market-ready solutions. More than 30 Business Matching sessions will be held to facilitate direct connections between entrepreneurs, investors, technology owners, and partners from both Thailand and abroad. The Prime Minister Awards, a prestigious national honor, will recognize organizations, startups, and collaborations that have created significant and measurable impact both nationally and internationally. Dr. Krithpaka concluded: 'NIA invites everyone with a creative spirit—innovators, investors, entrepreneurs, students, or those seeking new opportunities—to be part of SITE 2025. This is a platform to connect with global players, update on future trends, and create meaningful change together. It's also a critical opportunity to help drive Thailand forward in alignment with the 'Groom – Grant – Growth – Global' strategy.' The 30+ Business Matching rounds are designed to help entrepreneurs meet with investors and technology owners in a targeted and impactful way. Special Panel at the Press Conference: 'Accelerating Innovation Through Global Partnerships' This session highlighted cross-sector collaboration driving Thai innovation to the global stage. From the government perspective, Mr. Pariwat Wongsamran, Deputy Executive Director of Innovation System at NIA, said: 'Innovation today knows no national borders. What NIA is doing is not just about giving opportunities to entrepreneurs—it's about laying the foundation for an ecosystem that connects Thailand to the world in a tangible way. Through partnerships in Europe and Asia, we're not only focusing on current innovations but also building infrastructure to support long-term growth so that Thai startups can scale more sustainably.' Ms. Salinee Phonprapai, Deputy Director-General of the Department of International Economic Affairs, added: 'Innovation is now a key engine driving Thailand's economy. The Ministry of Foreign Affairs is pushing Thai startups onto the global stage through a network of 98 embassies and consulates worldwide. We're also working with partners like NIA, BOI, EEC, depa, and the Department of Trade Negotiations to promote investment, open new markets, and facilitate trade deals. In addition, visa policies are being introduced to attract global talent to enhance Thailand's innovation ecosystem.' On the private sector and innovation business side, Na Ranong, President of the Thai Venture Capital Association (TVCA), emphasized: 'Global partnership is the heart of modern investment. It increases business expansion opportunities and leads to higher value exits, particularly in hot sectors like AI and Deep Tech, which are drawing attention from global investors. Today's investors are looking for startups that can truly connect to the global network.' Mr. Thanawit Tonkanya, President of the Thai Startup Association (TSA), said: 'Thai startups must dream big, embrace international perspectives, and develop pitch skills that appeal to investors. SITE 2025 is a real-world arena for testing, connecting, and growing global networks.' 'Be part of the global change! and connect with innovators, creators, and investors shaping the future at SITE 2025.' The event will take place from July 4–6, 2025, at Paragon Hall, 5th Floor, Siam Paragon. Free entry! Register at: For more updates, follow on Facebook: NIA - National Innovation Agency Thailand, and Startup Thailand Hashtag: #NIA #SITE2025 #StartupThailand #InnovationThailand #DeepTech #AI #Sustainability #GlobalInnovationPartnership The issuer is solely responsible for the content of this announcement.
Associated Press
26 minutes ago
- Associated Press
The VinFast VF 6 Passes the Wife Test with Room to Spare
MANILA, PHILIPPINES - Media OutReach Newswire - 20 June 2025 - Women usually play an important role in family car-buying decisions, and the VinFast VF 6, recently launched in the Philippines, meets the key priorities of many women buyers. Photo The old stereotype paints a familiar picture: men kick tires, debate horsepower, and make the final call on family cars. Reality tells a different story. According to CDK Global, women influence 85% of all car purchases. This insight means that women play an important, sometimes deciding, role in buying a car. It's essential for automakers to understand what women actually look for in a vehicle. The way women make decisions The numbers reveal how women approach car buying. Women spend more time researching their options. On average, they take 75 days to make a decision, compared to 63 days for men. This suggests that they usually do more thorough research to build knowledge prior to the purchase. Their priorities are also different from men's when shopping for cars. An survey of over 500,000 car inquiries showed that women focus on price, affordability, and practical features, while performance specs and brand prestige rank lower. The cars men wanted cost three times more on average than what satisfied women buyers. This kind of thinking reflects the many roles women juggle every day: caregivers, professionals, and budget managers, often all at once. A MasterCard study across 16 Asian countries found women managing household finances in half the markets surveyed. In Indonesia and the Philippines, over 56% of women control domestic spending decisions. A more recent survey by Women's World Car of the Year gave a further breakdown. Safety ranks as the single most important feature women seek. Practicality, performance, and space tie for second place. But safety isn't just about crash ratings. Women want backup cameras, blind spot monitoring, and multiple airbags. They value high seating positions for better visibility. Storage pockets, cupholders, and intuitive technology matter for daily convenience. Many also weigh emissions and fuel efficiency, choosing greener options when the situation allows. VinFast VF 6 ticks all the boxes The VinFast VF 6, a compact SUV recently launched in the Philippines, happens to tick all the boxes that matter most to women car buyers. It's a fully electric SUV in the popular B-segment, combining safety, practicality, and smart technology in a package built for real-world use. In the Philippines, the VF 6 is available in two trims: Eco and Plus, with MSRPs of 1,419,000 PHP and 1,610,000 PHP respectively. The 'Natural Opposites' design, created with Torino Design, balances function and form. But looks aren't the selling point. It's the way the VF 6 fits into everyday life. With a 2,730 mm wheelbase, the VF 6 remains compact enough for narrow city streets while offering interior space comparable to many larger gas-powered cars in the C-segment. Its 423-liter cargo capacity fits around 10 standard carry-on suitcases. Folding down the rear seats makes room for larger items such as bicycles or camping gear. Inside, the VF 6 features a 12.9-inch infotainment screen, dual-zone climate control, rain-sensing wipers, and an 8-way power driver's seat. Voice commands operate smoothly. Utility modes cater to daily needs, including Pet Mode, which keeps the cabin cool for animals when the driver steps away. The 360-degree camera view also makes parking in tight spots easier. For safety, the VF 6 includes up to 8 airbags and offers up to 19 advanced driver assistance features in the Plus version. These include blind spot detection, rear parking assist, and 360-degree camera views, making driving easier for newer drivers. The VF 6's practicality extends to finances. Owners get free charging at V-GREEN operated stations until May 1st, 2027, which eliminates fuel costs entirely. The 7-year warranty and 90% buyback guarantee provide long-term security. Range anxiety disappears with up to 480 kilometers per charge, handling both daily commutes and weekend trips without compromise. 'Women hold up half the sky', so it's only natural that they should shape what families drive on the road. And the VF 6 happens to align perfectly with this shift toward practical buyers. In this era, automakers can't rely on dated assumptions. They need to meet people where they are, starting with the ones making the decisions. The VF 6 offers practical features, safety, and financial sense. That's what many buyers want, and that's how trust is earned. Hashtag: #VinFast The issuer is solely responsible for the content of this announcement.
Associated Press
26 minutes ago
- Associated Press
IBN Coverage: HeartBeam (NASDAQ: BEAT) Earns FDA Clearance for First Cable-Free ECG System for Arrhythmia Detection
This article was published by IBN, a multifaceted communications organization engaged in connecting public companies to the investment community. LOS ANGELES, CA - June 20, 2025 ( NEWMEDIAWIRE ) - HeartBeam (NASDAQ: BEAT) announced it has received FDA 510(k) clearance for its flagship ECG system, a first-of-its-kind, credit card-sized, cable-free device designed to deliver high-fidelity, three-directional cardiac recordings for arrhythmia evaluation. The clearance marks a major regulatory milestone and accelerates HeartBeam's plans to improve access to timely, remote cardiac care. When symptoms arise, patients use the app-guided system to record a 30-second ECG, which is automatically uploaded to the cloud for physician review in the context of medical history. The company will soon launch an Early Access Program to engage early adopters and providers ahead of broader commercialization. This foundational clearance also sets the stage for future advancements, including 12-lead ECG synthesis, AI-based arrhythmia detection, and remote heart attack risk scoring. HeartBeam's long-term vision is to revolutionize cardiac care by enabling continuous, predictive insights outside traditional clinical settings. To view the full press release, visit About HeartBeam Inc. HeartBeam is a medical technology company dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is. The company is creating the first-ever cable-free 12-lead ECG capable of capturing the heart's electrical signals from three dimensions. This platform technology is designed to be used in portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care - all outside of a medical facility, thus redefining the future of cardiac health management. The company holds 13 U.S. and 4 international-issued patents related to technology enablement. For more information, visit NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: The latest news and updates relating to BEAT are available in the company's newsroom at Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading 'Risk Factors' discussed under the caption 'Item 1A. Risk Factors' in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption 'Item 1A. Risk Factors' in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. About IBN IBN is a cutting-edge communications and digital engagement platform providing tailored Platform Solutions for select private and public companies. Over the course of 19+ years, IBN has introduced over 70 investor facing brands to the investment public and amassed a collective audience of millions of social media followers. These distinctive investor brands amplify recognition and reach as well as help fulfill the unique needs of our rapidly growing and diverse base of client-partners. IBN will continue to expand our branded network of influential properties as well as leverage the energy and experience of our team of professionals to best serve our clients. IBN's Platform Solutions provide access to: (1) our Dynamic Brand Portfolio (DBP) through 70+ investor facing brands; (2) article and editorial syndication to 5,000+ news outlets; (3) full-scale distribution to a growing Social Media Network (SMN) ; (4) a network of wire solutions via InvestorWire to effectively reach target markets and demographics; (5) Press Release Enhancement to ensure accuracy and impact; (6) a full array of corporate communications solutions; and (7) total news coverage solutions. For more information, please visit Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: Media Contact IBN Los Angeles, California 310.299.1717 Office [email protected]
